Protagenic Therapeutics closes $1.275M private placement of common stock and warrants

Protagenic Therapeutics, Inc.new

Closed private placement on Nov 4, 2024; sold 1,948,295 shares of common stock.
Issued series A warrants (18-month term) and series B warrants (5-year term), each exercisable at $0.64 per share.
Gross proceeds of $1.275M; net proceeds to be used for working capital.
Brookline Capital Markets acted as sole placement agent for the offering.
Warrants exercisable only after stockholder approval date; no proceeds from warrants included in gross proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.